![Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial,Vaccine - X-MOL Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial,Vaccine - X-MOL](https://xpic.x-mol.com/20210617%2F10.1016_j.vaccine.2021.05.067.jpg)
Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial,Vaccine - X-MOL
![Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine | Medical Microbiology and Immunology Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine | Medical Microbiology and Immunology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00430-014-0374-x/MediaObjects/430_2014_374_Fig1_HTML.gif)
Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine | Medical Microbiology and Immunology
![VBI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac® Meets Primary and Secondary Endpoints - VBI Vaccines VBI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac® Meets Primary and Secondary Endpoints - VBI Vaccines](https://www.vbivaccines.com/wp-content/uploads/2020/01/Sci-B-Vac%C2%AE-CONSTANT-Phase-III-Top-Line-Data.jpg)
VBI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac® Meets Primary and Secondary Endpoints - VBI Vaccines
![Vaccines | Free Full-Text | Efficacy of Birth Dose Vaccination in Preventing Mother-to-Child Transmission of Hepatitis B: A Randomized Controlled Trial Comparing Engerix-B and Sci-B-Vac Vaccines | Free Full-Text | Efficacy of Birth Dose Vaccination in Preventing Mother-to-Child Transmission of Hepatitis B: A Randomized Controlled Trial Comparing Engerix-B and Sci-B-Vac](https://www.mdpi.com/vaccines/vaccines-09-00331/article_deploy/html/images/vaccines-09-00331-g001-550.jpg)
Vaccines | Free Full-Text | Efficacy of Birth Dose Vaccination in Preventing Mother-to-Child Transmission of Hepatitis B: A Randomized Controlled Trial Comparing Engerix-B and Sci-B-Vac
![Analysis Of SCI-B-VAC's Overwhelming Phase III Clinical Data Suggests VBI Vaccines' Share Price Is Materially Undervalued (NASDAQ:VBIV) | Seeking Alpha Analysis Of SCI-B-VAC's Overwhelming Phase III Clinical Data Suggests VBI Vaccines' Share Price Is Materially Undervalued (NASDAQ:VBIV) | Seeking Alpha](https://static.seekingalpha.com/uploads/2020/1/12/50434696-15788834741488392_origin.png)
Analysis Of SCI-B-VAC's Overwhelming Phase III Clinical Data Suggests VBI Vaccines' Share Price Is Materially Undervalued (NASDAQ:VBIV) | Seeking Alpha
![Development of Sci B Vac: a Pre-S 1 /Pre-S 2 /S Hepatitis B Vaccine Daniel Shouval Liver Unit Hadassah and Hebrew University JerusalemIsrael. - ppt download Development of Sci B Vac: a Pre-S 1 /Pre-S 2 /S Hepatitis B Vaccine Daniel Shouval Liver Unit Hadassah and Hebrew University JerusalemIsrael. - ppt download](https://slideplayer.com/5289671/17/images/slide_1.jpg)
Development of Sci B Vac: a Pre-S 1 /Pre-S 2 /S Hepatitis B Vaccine Daniel Shouval Liver Unit Hadassah and Hebrew University JerusalemIsrael. - ppt download
![Analysis Of SCI-B-VAC's Overwhelming Phase III Clinical Data Suggests VBI Vaccines' Share Price Is Materially Undervalued (NASDAQ:VBIV) | Seeking Alpha Analysis Of SCI-B-VAC's Overwhelming Phase III Clinical Data Suggests VBI Vaccines' Share Price Is Materially Undervalued (NASDAQ:VBIV) | Seeking Alpha](https://static.seekingalpha.com/uploads/2020/1/12/50434696-1578884140491947_origin.png)